{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T07:14:01Z","timestamp":1788160441816,"version":"build-2803163510"},"reference-count":30,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Mark. Access Health Policy","JMAHP"],"abstract":"<jats:p>Health technology assessment is a discipline that has developed, over five decades, an elaborate scientific and institutional identity centered on the evaluation of clinical evidence, comparative effectiveness, and economic value [...]<\/jats:p>","DOI":"10.3390\/jmahp14030052","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:55:56Z","timestamp":1788155756000},"page":"52","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Procedural Theatre: EU-HTA Between Ritual and Purpose\u2014Why the Buyer\u2019s Audit Has Outgrown the Transaction"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7939-7204","authenticated-orcid":false,"given":"Mondher","family":"Toumi","sequence":"first","affiliation":[{"name":"CEReSS\/UR3279\u2014Health Services Research and Quality of Life Center, Aix-Marseille University, 13385 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten Jacobus","family":"Postma","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University Medical Center Groningen, University of Groningen, 9700 AB Groningen, The Netherlands"},{"name":"Department of Economics, Econometrics & Finance, Faculty of Economics & Business, University of Groningen, 9713 AB Groningen, The Netherlands"},{"name":"Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung 40132, Indonesia"},{"name":"Division of Pharmacology & Therapy, Faculty of Medicine, Universitas Airlangga, Surabaya 60131, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Falissard","sequence":"additional","affiliation":[{"name":"CESP, INSERM U1018, Universit\u00e9 Paris-Saclay, 94800 Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank-Ulrich","family":"Fricke","sequence":"additional","affiliation":[{"name":"Fachbereich Betriebswirtschaft, Technische Hochschule N\u00fcrnberg, 90402 N\u00fcrnberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4633-4420","authenticated-orcid":false,"given":"Stefano","family":"Capri","sequence":"additional","affiliation":[{"name":"School of Economics and Management, Cattaneo-LIUC University, 21053 Castellanza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9653-168X","authenticated-orcid":false,"given":"J\u00fcrgen","family":"Wasem","sequence":"additional","affiliation":[{"name":"Institute of Healthcare Management, Universit\u00e4t Duisburg-Essen, 45127 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9512-2005","authenticated-orcid":false,"given":"Steven","family":"Simoens","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, Katholieke Universiteit Leuven, 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Bernardini","sequence":"additional","affiliation":[{"name":"Section of Pharmacology, Department of Biomedical and Biotechnological Sciences (BIOMETEC), University of Catania, 95124 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Wojtal","sequence":"additional","affiliation":[{"name":"Clever-Access, 30-415 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kapu\u015bniak","sequence":"additional","affiliation":[{"name":"Clever-Access, 30-415 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol Sola","family":"Morales","sequence":"additional","affiliation":[{"name":"HiTT Foundation, 08015 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1229-6622","authenticated-orcid":false,"given":"Laurent","family":"Boyer","sequence":"additional","affiliation":[{"name":"CEReSS\/UR3279\u2014Health Services Research and Quality of Life Center, Aix-Marseille University, 13385 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7299-6554","authenticated-orcid":false,"given":"Jaime","family":"Espin","sequence":"additional","affiliation":[{"name":"Andalusian School of Public Health\/Escuela Andaluza de Salud P\u00fablica (EASP), 18011 Granada, Spain"},{"name":"CIBER of Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Biosanitaria, 18012 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3496-1996","authenticated-orcid":false,"given":"Pascal","family":"Auquier","sequence":"additional","affiliation":[{"name":"CEReSS\/UR3279\u2014Health Services Research and Quality of Life Center, Aix-Marseille University, 13385 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"ref_1","unstructured":"Drummond, M.F., Sculpher, M.J., Claxton, K., Stoddart, G.L., and Torrance, G.W. (2015). Methods for the Economic Evaluation of Health Care Programmes, Oxford University Press. [4th ed.]."},{"key":"ref_2","unstructured":"Sorenson, C., Drummond, M., and Kanavos, P. (2008). Ensuring Value for Money in Health Care: The Role of Health Technology Assessment in the European Union, WHO Regional Office for Europe. Observatory Studies Series No. 11."},{"key":"ref_3","first-page":"941","article-title":"Uncertainty and the welfare economics of medical care","volume":"53","author":"Arrow","year":"1963","journal-title":"Am. Econ. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/00019053-200826090-00004","article-title":"The NICE cost-effectiveness threshold: What it is and what that means","volume":"26","author":"McCabe","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19140","article-title":"Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold","volume":"19","author":"Claxton","year":"2015","journal-title":"Health Technol. Assess."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13561-016-0109-3","article-title":"Benefit assessment in Germany: Implications for price discounts","volume":"6","author":"Theidel","year":"2016","journal-title":"Health Econ. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jval.2021.06.013","article-title":"Coverage and pricing recommendations of the French National Health Authority for innovative drugs: A retrospective analysis from 2014 to 2020","volume":"24","author":"Kergall","year":"2021","journal-title":"Value Health"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1344088","DOI":"10.1080\/20016689.2017.1344088","article-title":"Analysis of health economics assessment reports for pharmaceuticals in France\u2014Understanding the underlying philosophy of CEESP assessment","volume":"5","author":"Toumi","year":"2017","journal-title":"J. Mark. Access Health Policy"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40273-014-0144-z","article-title":"A comparative analysis of two contrasting European approaches for rewarding the value added by drugs for cancer: England versus France","volume":"32","author":"Drummond","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s10198-016-0823-0","article-title":"Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries","volume":"18","author":"Nicod","year":"2017","journal-title":"Eur. J. Health Econ."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jval.2016.08.725","article-title":"Variation in health technology assessment and reimbursement processes in Europe","volume":"20","author":"Akehurst","year":"2017","journal-title":"Value Health"},{"key":"#cr-split#-ref_12.1","unstructured":"European Union (2021). Regulation"},{"key":"#cr-split#-ref_12.2","unstructured":"(EU) 2021\/2282 of the European Parliament and of the Council of 15 December 2021 on Health Technology Assessment and Amending Directive 2011\/24\/EU. Off. J. Eur. Union, L 458, 1-32."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s40273-015-0370-z","article-title":"Value-based assessment of new medical technologies: Towards a robust methodological framework for the application of multiple criteria decision analysis in the context of health technology assessment","volume":"34","author":"Angelis","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1017\/S0266462308080343","article-title":"Key principles for the improved conduct of health technology assessments for resource allocation decisions","volume":"24","author":"Drummond","year":"2008","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jval.2018.08.010","article-title":"Identifying the need for good practices in health technology assessment: Summary of the ISPOR HTA Council Working Group report on good practices in HTA","volume":"22","author":"Kristensen","year":"2019","journal-title":"Value Health"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Jaros\u0142awski, S., and Toumi, M. (2011). Market access agreements for pharmaceuticals in Europe: Diversity of approaches and underlying concepts. BMC Health Serv. Res., 11.","DOI":"10.1186\/1472-6963-11-259"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.healthpol.2010.02.005","article-title":"Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers","volume":"96","author":"Carlson","year":"2010","journal-title":"Health Policy"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jval.2013.04.011","article-title":"Performance-based risk-sharing arrangements\u2014Good practices for design, implementation, and evaluation: Report of the ISPOR good practices for performance-based risk-sharing arrangements task force","volume":"16","author":"Garrison","year":"2013","journal-title":"Value Health"},{"key":"ref_19","unstructured":"Tainter, J.A. (1988). The Collapse of Complex Societies, Cambridge University Press."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3390\/jmahp12020008","article-title":"EU HTA regulation and joint clinical assessment\u2014Threat or opportunity?","volume":"12","author":"Schuster","year":"2024","journal-title":"J. Mark. Access Health Policy"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13561-022-00402-x","article-title":"Shaping a research agenda to ensure a successful European health technology assessment: Insights generated during the inaugural convention of the European Access Academy","volume":"12","author":"Julian","year":"2022","journal-title":"Health Econ. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Toumi, M., Falissard, B., Boyer, L., and Auquier, P. (2025). Joint scientific consultation eligibility criterion: Hubris or na\u00efvet\u00e9?. J. Mark. Access Health Policy, 13.","DOI":"10.3390\/jmahp13020022"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1017\/S0266462324004641","article-title":"Impact of indication changes on scoping for European Union Joint Clinical Assessment: Scale of the problem and how to address it","volume":"40","author":"Heikkinen","year":"2024","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Eberle, K., Hagemann, L.M., Schweitzer, M.K., Justl, M., Maurer, J., Carls, A., and Reuter, E.M. (2025). The PICO puzzle: Can public data predict EU HTA expectations for all EU countries?. J. Mark. Access Health Policy, 13.","DOI":"10.3390\/jmahp13030032"},{"key":"ref_25","unstructured":"Claxton, K., Sculpher, M., and Carroll, S. (2011). Value-Based Pricing for Pharmaceuticals: Its Role, Specification and Prospects in a Newly Devolved NHS, Centre for Health Economics, University of York. CHE Research Paper No. 60."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40273-012-0001-x","article-title":"Operationalizing value-based pricing of medicines: A taxonomy of approaches","volume":"31","author":"Sussex","year":"2013","journal-title":"Pharmacoeconomics"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/hec.3021","article-title":"Value-based differential pricing: Efficient prices for drugs in a global context","volume":"24","author":"Danzon","year":"2015","journal-title":"Health Econ."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Toumi, M., Falissard, B., Jouini, A., Aball\u00e9a, S., and Boyer, L. (2025). Clinical trial validity guidance from the HTACG: Looking for chicken teeth. J. Mark. Access Health Policy, 13.","DOI":"10.3390\/jmahp13020015"},{"key":"ref_29","first-page":"185","article-title":"\u00dcber die isolirte F\u00e4rbung der Schizomyceten in Schnitt- und Trockenpr\u00e4paraten","volume":"2","author":"Gram","year":"1884","journal-title":"Fortschr. Med."}],"container-title":["Journal of Market Access &amp; Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2001-6689\/14\/3\/52\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T06:22:22Z","timestamp":1788157342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2001-6689\/14\/3\/52"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jmahp14030052"],"URL":"https:\/\/doi.org\/10.3390\/jmahp14030052","relation":{},"ISSN":["2001-6689"],"issn-type":[{"value":"2001-6689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]}}}